Orthocell Limited (OCC.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.535 (+8.08%) as of
Key statistics
- Market cap
- 145.73M
- Forward P/E
- -22.77
- EPS (TTM)
- -0.0500
- Dividend yield
- 0.00%
- 52-week range
- 0.4900 – 1.2700
- Beta
- -0.03
- Revenue (TTM)
- 11.41M
- Profit margin
- -121.98%
- Analyst target
- A$0.90
- Volume
- 1.03M
About Orthocell Limited
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; OrthoATI, for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental applications; and Remplir, a collagen scaffold used in peripheral nerve repair. The company also develops Collagen Medical Device platform products for bone, nerve, tendon, muscle, or scar tissue, and ligament repair; and Tendon Cell Therapy for rotator cuff and lateral epicondyle indications. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Murdoch, WA, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.